Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 3
2006 3
2007 1
2008 3
2009 1
2010 2
2011 5
2012 1
2013 1
2014 2
2015 2
2016 4
2017 3
2018 2
2019 6
2020 5
2021 3
2022 1
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
[Therapeutic drug monitoring].
Le Guellec C, Bentué-Ferrer D; groupe STP de la SFPT. Le Guellec C, et al. Therapie. 2010 Jan-Feb;65(1):13-5. Therapie. 2010. PMID: 20443240 French. No abstract available.
Niveau de preuve du suivi thérapeutique pharmacologique des aminosides.
Venisse N, Boulamery A; pour le groupe Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique. Venisse N, et al. Therapie. 2011 Jan-Feb;66(1):39-44. doi: 10.2515/therapie/2011001. Therapie. 2011. PMID: 27393463 French.
BPA and risk assessment.
Dupuis A, Rabouan S, Migeot V, Venisse N. Dupuis A, et al. Among authors: venisse n. Lancet Diabetes Endocrinol. 2020 Apr;8(4):270-271. doi: 10.1016/S2213-8587(20)30069-3. Lancet Diabetes Endocrinol. 2020. PMID: 32197111 No abstract available.
Niveau de preuve du suivi thérapeutique pharmacologique de la teicoplanine.
Boulamery A, Venisse N, Le Guellec C; pour le groupe Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique. Boulamery A, et al. Among authors: venisse n. Therapie. 2011 Jan-Feb;66(1):45-50. doi: 10.2515/therapie/2011003. Therapie. 2011. PMID: 27393464 French.
Comment on: Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV.
Benaboud S, Solas C, Bouchet S, Gregoire M, Lemaitre F, Venisse N, Lê MP, Muret P, Parant F, Neant N, Boujafaar S, Lagoutte-Renosi J, Garraffo R, Peytavin G. Benaboud S, et al. Among authors: venisse n. J Antimicrob Chemother. 2023 Mar 2;78(3):853-854. doi: 10.1093/jac/dkad009. J Antimicrob Chemother. 2023. PMID: 36683308 No abstract available.
Isavuconazole Kinetic Exploration for Clinical Practice.
Darnaud L, Lamoureux F, Godet C, Pontier S, Debard A, Venisse N, Martins P, Concordet D, Gandia P. Darnaud L, et al. Among authors: venisse n. Drugs R D. 2018 Dec;18(4):317-321. doi: 10.1007/s40268-018-0251-y. Drugs R D. 2018. PMID: 30306415 Free PMC article.
Trends in Fatal Poisoning Among Drug Users in France From 2011 to 2021: An Analysis of the DRAMES Register.
Revol B, Willeman T, Manceau M, Dumestre-Toulet V, Gaulier JM, Fouilhé Sam-Laï N, Eysseric-Guérin H; Compagnie Nationale des Biologistes et Analystes Experts (CNBAE) and the French Addictovigilance Network (FAN). Revol B, et al. JAMA Netw Open. 2023 Aug 1;6(8):e2331398. doi: 10.1001/jamanetworkopen.2023.31398. JAMA Netw Open. 2023. PMID: 37647066 Free PMC article.
Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.
Venisse N, Peytavin G, Bouchet S, Gagnieu MC, Garraffo R, Guilhaumou R, Solas C; ANRS-AC43 Clinical Pharmacology Committee, SFPT Therapeutic Drug Monitoring and Treatment Personalization group. Venisse N, et al. Antiviral Res. 2020 Sep;181:104866. doi: 10.1016/j.antiviral.2020.104866. Epub 2020 Jul 10. Antiviral Res. 2020. PMID: 32659293 Free PMC article. Review.
50 results